JP5970459B2 - がん診断用バイオマーカーに対する骨髄細胞の使用 - Google Patents
がん診断用バイオマーカーに対する骨髄細胞の使用 Download PDFInfo
- Publication number
- JP5970459B2 JP5970459B2 JP2013528723A JP2013528723A JP5970459B2 JP 5970459 B2 JP5970459 B2 JP 5970459B2 JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013528723 A JP2013528723 A JP 2013528723A JP 5970459 B2 JP5970459 B2 JP 5970459B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mdsc
- patients
- treatment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
表1:PBMC中に発見され、主な文献で報告されたヒトMDSC表現型
表2:優先順位順のヒトMDSCマーカーの選択(括弧内のマーカーは任意選択)
a)MDSC1、マーカーIL4Ra+およびCD14+に基づき同定可能
b)MDSC2、マ-カーIL4Ra+とCD15+に基づき同定可能
c)マーカーIL4Ra+に基づき同定可能、および/またはマーカーIL4Ra+に基づきその他のMDSC2〜6または1と3〜6を識別可能であるMDSC1または2のグループ
d)MDSC3、マーカーLin-、HLA-DR-、およびCD33+に基づき、選択的にCD18+およびHLAI+も一緒に、同定可能
e)MDSC4、マーカーCD14+、HLA-DR(-/lo)、FSChiおよびSSCimに基づき同定可能
f)MDSC5、マーカーCD11b+、CD14-およびCD15+に基づき、選択的にFSChi、SSCim、CD80-、CD83-、CD86-およびHLA-DR-と一緒に同定可能
g)CD15+、FSCloおよびSSChiに基づくMDSC6
ハザード比>1(下線):高い値を有する患者はイベント発症までの時間が短い。Cy=シクロホスファミドによる前治療
(a)上述の免疫原性TAAペプチドおよび/または抗体の組成物(溶液または凍結乾燥物)を含む容器と、
(b)選択的に、凍結乾燥調製物の希釈剤あるいは再溶解溶液を含む第2容器と、
(d)選択的に、(i)溶液の使用、または(ii)凍結乾燥調製物の再溶解および/または使用の説明とを有するキットを含む。
治療前レベルの健常ドナーとの比較では、70歳未満のintention-to-treat(ITT)患者のみを選択し、最年長健常対照ドナーとマッチさせた。得られた患者(N=52)と健常ドナー(N=22)群の年齢、性別、およびCMV血清反応陽性を合わせた。MDSC1レベルは患者と健常ドナー間で異なる一方、MDSC2、3、4、5および6は、健常ドナーと比較し、患者において大きく有意に増加することが分かった。
MDSC評価可能なITT集団(N=61)内で、両試験群(+または-Cy)のMDSC1〜6レベルを合わせたため、有意な差を示さなかったことが分かった。ソラフェニブの治療前投与は、治療前MDSC2レベルの有意な低下と関連していた(p=0.0278[Mann-Whitney検定];MDSC1レベルと同じ傾向)。これらのデータは、ソラフェニブが骨髄成熟過程に影響を与える可能性があるという仮説と一致している。関連があると考えられる事前の所見は、ソラフェニブが、PI3とMAPキナーゼ、およびNFκBシグナル伝達の阻害により、in vitroでヒトDCの成熟を阻害することを示したことである。
治療前MDSCレベルと免疫応答の相関は、Per Protocol PP 患者集団において、評価可能な治療前MDSCレベルと評価可能な全免疫応答(N=54)を利用して解析した。サブグループ解析は、CYの前治療の有/無に関して実施した。免疫応答の増加と治療前MDSC1-6レベルの低下との全体的な関連性は、全PP患者集団で認められなかった。興味深いことに、CYサブグループのみで、複数のTUMAPに対する免疫応答がMDSC5レベルの低下に関連する強い傾向があった(p=0.0524;両側Mann-Whitney 検定)。
全PP患者集団の治療前MDSCレベルを全生存率と比較すると(評価可能N=57)、いくつかの有意な相関(MDSC4、5)と傾向(MDSC3、6)が認められた。仮説通り、治療前MDSCレベルの増加は常に全生存率の短縮に関連していた。そのため、MDSCの明確なバイオマーカーの役割が、疾患の予後徴候となるか、またはIMA901治療への応答を予測する、IMA901-202で確認された。いくつかのMDSC表現型について、予後的vs予測的マーカーを区別する傾向は、IMA901への免疫応答を呈した患者およびCYで前治療した患者においてより顕著であり、このことは、おそらく、(この例では)IMA901により誘発されるT細胞応答の機能性を阻害することより、IMA901誘発T細胞応答の有効性に影響を与える、予測バイオマーカーとしての役割を示している。
治療前の一時点で試験可能な全IMA901-202患者から得たPBMC、つまりマッチした健常ドナーPBMCおよび内部標準PBMC(治療前データセット)を使用し、IMA901-202サンプルについて、(予め定義したように)アッセイを実施した。
末梢血単核細胞(PBMC)は、標準のFicoll勾配分離によってヘパリン添加血液サンプルから8時間以内に得て、バッチ分析前に冷凍保存した。
Claims (14)
- 患者から得た生体サンプル中の骨髄由来免疫抑制細胞(MDSC)4表現型レベルを、MDSC4表現型マーカーに基づき決定することを含む、がんの診断および/または予測を補助するための検査方法であって、
前記マーカーは、CD14+、HLA-DR(-/lo)、FSChi、およびSSCimであり、非がん患者サンプルと比較した前記MDSC4表現型レベルの増加は、がんを示すか、および/または前記がん治療の予後指標となる、方法。 - がんは、腎細胞癌(RCC)、大腸癌(CRC)、胃癌(GC)、メラノーマ、および腺癌から選択される、請求項1に記載の方法。
- 1つの多色染色ステップを含むフローサイトメトリを有する、請求項1または2に記載の方法。
- さらに治療の予後の予測の補助を含むものであって、サンプル中の治療前MDSC4表現型レベルに比べたMDSC4表現型レベルの増加が、全生存率の短縮、腫瘍の増殖、または無増悪生存率に関係する、請求項1〜3のいずれかに記載の方法。
- MDSC4表現型は、病期IVメラノーマ患者のMDSC4である、請求項1〜4のいずれか一に記載の方法。
- 生体サンプルは、末梢血単核細胞(PBMC)、全血、末梢血、またはその分画であるバッフィーコート、腫瘍組織、および骨髄を含むサンプルから選択される、請求項1〜5に記載の方法。
- がん治療中の患者から得た生体サンプル中の骨髄由来免疫抑制細胞(MDSC)4表現型レベルを決定し、患者のがん治療の効果を検出することを補助するものであって、非治療患者サンプルに比べた前記MDSC4表現型レベルの減少が、前記患者の前記がんの治療に有効であることを示す、請求項1〜6のいずれか一に記載の方法。
- 患者はサイトカイン、ソラフェニブ、スニチニブ、シクロホスファミド、およびチロシンキナーゼ阻害薬(TKI)から選ばれる抗がん剤で治療または前治療される、請求項7に記載の方法。
- さらに、がん治療の効果のモニタリングを補助すること、1回以上請求項7に記載の決定するステップを繰り返すことを含む、請求項7または8に記載の方法。
- がん治療は、抗がんワクチンの使用を含み、選択的にGM-CSFを併用する、化学療法および/または免疫療法から選択される、請求項7〜9のいずれか一に記載の方法。
- 抗がんワクチンは、配列番号1〜10、配列番号11〜19と1、5、8、および9、配列番号20〜29、さらに配列番号30〜37から選択される配列を含む免疫原性ペプチド混合物からなる抗がんワクチンから選ばれる、請求項10に記載の方法。
- CD14に特異的な抗体およびHLA-DRに特異的な抗体を含み、1つまたは別々の容器で請求項1〜11のいずれか一に記載の方法を実施する材料を含み、選択的に前記方法を実施するための説明書が添付される、診断キット。
- 抗体はQ605、V450、AF700、APC-H7、Cy7およびFITCから選択されるサイトメトリマーカーで標識される、請求項12に記載の診断キット。
- CD14 APC-H7およびCD14 FITCから選択される1つ以上の抗体を含む、請求項12または13に記載の診断キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38478410P | 2010-09-21 | 2010-09-21 | |
US61/384,784 | 2010-09-21 | ||
GB1015765.9 | 2010-09-21 | ||
GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013539857A JP2013539857A (ja) | 2013-10-28 |
JP2013539857A5 JP2013539857A5 (ja) | 2014-10-30 |
JP5970459B2 true JP5970459B2 (ja) | 2016-08-17 |
Family
ID=43065538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013528723A Expired - Fee Related JP5970459B2 (ja) | 2010-09-21 | 2011-09-21 | がん診断用バイオマーカーに対する骨髄細胞の使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9671404B2 (ja) |
EP (1) | EP2619585B1 (ja) |
JP (1) | JP5970459B2 (ja) |
KR (1) | KR20130137635A (ja) |
CN (1) | CN103180739B (ja) |
CA (1) | CA2811070A1 (ja) |
EA (1) | EA201390413A1 (ja) |
GB (1) | GB201015765D0 (ja) |
SG (2) | SG188543A1 (ja) |
WO (1) | WO2012038463A2 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
CN103608028A (zh) * | 2011-04-28 | 2014-02-26 | 南加利福尼亚大学 | 人类髓源抑制性细胞癌症标记 |
WO2013169913A1 (en) | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
CA2990852A1 (en) * | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
CN116893262A (zh) * | 2015-09-02 | 2023-10-17 | 赛达克斯制药股份有限公司 | 用于组合疗法的患者的选择 |
BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
MX2018012434A (es) | 2016-04-14 | 2019-06-06 | Ose Immunotherapeutics | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas. |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗SIRPa抗体及びその使用 |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
EA202091859A1 (ru) | 2018-03-13 | 2021-02-04 | Осе Иммьюнотерапьютикс | Применение антител к sirpa v1 человека и способ получения антител к sirpa v1 |
ES2939357T3 (es) | 2018-05-07 | 2023-04-21 | Syndax Pharmaceuticals Inc | Selección de pacientes para terapia de combinación |
CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
AU2022284373A1 (en) | 2021-06-04 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
- 2011-09-21 US US13/239,011 patent/US9671404B2/en active Active
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Application Discontinuation
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en active Application Filing
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012038463A3 (en) | 2012-07-26 |
SG188543A1 (en) | 2013-04-30 |
CN103180739A (zh) | 2013-06-26 |
EP2619585B1 (en) | 2017-03-01 |
US9671404B2 (en) | 2017-06-06 |
WO2012038463A2 (en) | 2012-03-29 |
SG10201510470WA (en) | 2016-01-28 |
CA2811070A1 (en) | 2012-03-29 |
US20120070461A1 (en) | 2012-03-22 |
EP2619585A2 (en) | 2013-07-31 |
JP2013539857A (ja) | 2013-10-28 |
GB201015765D0 (en) | 2010-10-27 |
EA201390413A1 (ru) | 2013-07-30 |
CN103180739B (zh) | 2016-08-03 |
KR20130137635A (ko) | 2013-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5970459B2 (ja) | がん診断用バイオマーカーに対する骨髄細胞の使用 | |
Edwards et al. | CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti–PD-1 treatment | |
Fujii et al. | Biomarkers of response to immune checkpoint blockade in cancer treatment | |
Wang et al. | Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer | |
JP5774309B2 (ja) | 癌マーカーおよび治療ターゲット | |
Fujioka et al. | Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication | |
US10738119B2 (en) | Combination therapy for hepatocellular carcinoma | |
EP3022561B1 (en) | Method for the prognosis of survival time of a patient suffering from a solid cancer | |
Hu et al. | Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1 | |
Yu et al. | Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer | |
Kazama et al. | Distribution of regulatory T-cells and other phenotypes of T-cells in tumors and regional lymph nodes of colorectal cancer patients | |
US20210017607A1 (en) | Methods of Predicting Responsiveness to Cancer Therapies | |
WO2010066858A1 (en) | Methods for the treatment and the prognosis of cancer | |
Heng et al. | High expression of tumor HLA-DR predicts better prognosis and response to anti-PD-1 therapy in laryngeal squamous cell carcinoma | |
Liu et al. | FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays | |
Kazimierczak et al. | BNIP3L is a new autophagy related prognostic biomarker for melanoma patients treated with AGI-101H | |
WO2013109944A1 (en) | Methods for assessing risk for cancer using biomarkers | |
Camcı et al. | Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer | |
WO2010123124A1 (ja) | 固形がんの再発および予後因子、およびその臨床利用 | |
JP7042753B2 (ja) | 免疫チェックポイント阻害剤の投与対象となる個体の選択方法 | |
JP7255896B2 (ja) | シクロホスファミド療法に対する応答者の予測 | |
Kostine | Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients? | |
Currenti et al. | Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response | |
Gerard et al. | Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms | |
Yap et al. | Please let us know how this document benefits you. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140909 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140909 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150713 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160212 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160411 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160705 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160711 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5970459 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |